SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-24-035806
Filing Date
2024-11-20
Accepted
2024-11-20 09:00:45
Documents
17
Period of Report
2024-11-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20241120_8k.htm   iXBRL 8-K 36941
2 EXHIBIT 10.1 ex_750345.htm EX-10.1 64400
3 EXHIBIT 99.1 ex_750346.htm EX-99.1 13377
8 logo01.jpg GRAPHIC 2794
  Complete submission text file 0001437749-24-035806.txt   296091

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20241118.xsd EX-101.SCH 3872
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20241118_def.xml EX-101.DEF 13797
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20241118_lab.xml EX-101.LAB 18159
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20241118_pre.xml EX-101.PRE 13829
19 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20241120_8k_htm.xml XML 4834
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 241478386
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)